The development of recombinant subunit Envelop-based vaccines to protect against dengue virus induced disease

Author(s): Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH


Challenges associated with the interference observed between the dengue virus components within early tetravalent live-attenuated vaccines led many groups to explore the development of recombinant subunit based vaccines. Initial efforts in the field were hampered by low yields and/or improper folding, but the use of the Drosophila S2 cell expression system provided a mechanism to overcome these limitations. The truncated dengue envelope proteins (DEN-80E) for all four dengue virus types are expressed in the S2 system at high levels and have been shown to maintain native-like conformation. The DEN-80E proteins are potent immunogens when formulated with a variety of adjuvants, inducing high titer virus neutralizing antibody responses and demonstrating protection in both mouse and non-human primate models. Tetravalent vaccine formulations have shown no evidence of immune interference between the four DEN-80E antigens in preclinical models. Based on the promising preclinical data, the recombinant DEN-80E proteins have now advanced into clinical studies. An overview of the relevant preclinical data for these recombinant proteins is presented in this review.

Similar Articles

Zika Virus: Medical Countermeasure Development Challenges

Author(s): Malone RW, Homan J, Callahan MV, Glasspool-Malone J, Damodaran L, et al.

Zika Virus

Author(s): Centers for Disease Control and Prevention

Additional area of active Zika transmission identified in Miami Beach

Author(s): Centers for Disease Control and Prevention

Zika virus and birth defects-reviewing the evidence for causality

Author(s): Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR

Predicting Zika virus structural biology

Author(s): Cox BD, Stanton RA, and Schinazi RF

Structure of the thermally stable Zika virus

Author(s): Kostyuchenko VA, Lim E, Zhang S, Fibriansah G, Ng TS, et al.